News & Updates

Show Multimedia Only

Add-on olanzapine prevents RT-induced nausea, vomiting

01 Jul 2025 by

In patients undergoing abdominal-pelvic radiation therapy (RT), treatment with olanzapine along with an antiemetic medication leads to a substantial decrease in RT-induced nausea and vomiting (RINV), with no serious adverse effects, reports a study presented at ASCO 2025.

Add-on olanzapine prevents RT-induced nausea, vomiting

01 Jul 2025

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

01 Jul 2025

High-dose aumolertinib appears to provide progression-free survival (PFS) benefit to patients with untreated EGFR-variant non–small cell lung cancer (NSCLC) and brain metastases, while having a manageable safety profile, according to the results of a single-arm phase II study.

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

01 Jul 2025

Tofacitinib better than azathioprine as maintenance in steroid-responsive acute severe UC

30 Jun 2025

In patients with steroid-responsive acute severe ulcerative colitis (UC), maintenance therapy with tofacitinib appears to be more effective at maintaining remission when compared with azathioprine, according to a study.

Tofacitinib better than azathioprine as maintenance in steroid-responsive acute severe UC

30 Jun 2025

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Treatment of immune checkpoint inhibitors (ICIs) has led to a more than twofold increase in survival for patients with advanced Merkel cell carcinoma (MCC) at the population level, translating to about 220 fewer deaths annually in the US, according to a study.

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

30 Jun 2025 by

In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

30 Jun 2025

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

30 Jun 2025

Treatment with the novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist ecnoglutide for weight management is safe and results in substantial and sustained weight loss in adults with obesity or overweight but without diabetes, according to a phase III study.

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

30 Jun 2025

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025 by

The oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI) zongertinib confers clinically meaningful benefit to patients with previously treated HER2-mutant nonsmall cell lung cancer (NSCLC), including those with brain metastases, while having a manageable safety profile, according to the phase 1A/1B Beamion LUNG-1 trial.

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025

Early HCQ treatment prevents progression of CLE to SLE

29 Jun 2025

Early initiation of hydroxychloroquine (HCQ) protects patients with cutaneous lupus erythematosus (CLE) from progressing to systemic lupus erythematosus (SLE), a recent study has shown.

Early HCQ treatment prevents progression of CLE to SLE

29 Jun 2025

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

28 Jun 2025

Exposure to biologics for inflammatory bowel disease (IBD) in utero or during breastfeeding does not appear to impair psychomotor development in infants, according to a study.

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

28 Jun 2025

Low intensity heparin strategy safe for patients on ECMO

27 Jun 2025

The incidence of any bleeding or thrombotic events does not differ when using low or standard intensity heparin protocol in patients on extracorporeal membrane oxygenation (ECMO), reports a recent study.

Low intensity heparin strategy safe for patients on ECMO

27 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Add-on olanzapine prevents RT-induced nausea, vomiting

Add-on olanzapine prevents RT-induced nausea, vomiting

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

Aumolertinib shows promise in untreated EGFR-variant metastatic NSCLC

Tofacitinib better than azathioprine as maintenance in steroid-responsive acute severe UC

Tofacitinib better than azathioprine as maintenance in steroid-responsive acute severe UC

ICIs improve survival in advanced MCC at population level

ICIs improve survival in advanced MCC at population level

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

Ecnoglutide serves up weight-loss benefit for nondiabetic adults with overweight, obesity

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Early HCQ treatment prevents progression of CLE to SLE

Early HCQ treatment prevents progression of CLE to SLE

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

Infant psychomotor development not harmed by biologic exposure in utero, during breastfeeding

Low intensity heparin strategy safe for patients on ECMO

Low intensity heparin strategy safe for patients on ECMO